Shaoyi Li

Title: Innovations of Shaoyi Li in Hepatocellular Carcinoma Treatment

Introduction

Shaoyi Li is an accomplished inventor based in Warren, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) infection. His innovative approach has the potential to improve patient outcomes in this challenging area of healthcare.

Latest Patents

Shaoyi Li holds a patent for a method that focuses on the treatment and prevention of hepatocellular carcinoma characterized by hepatitis B virus infection. The patent details the administration of an effective amount of a specific compound, 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, or its pharmaceutically acceptable salt or tautomer. This innovative treatment aims to provide new hope for patients suffering from HCC linked to HBV infection.

Career Highlights

Shaoyi Li is currently associated with Celgene Corporation, a leading biopharmaceutical company known for its focus on innovative therapies. His work at Celgene has allowed him to collaborate with other talented professionals in the field, contributing to advancements in cancer treatment.

Collaborations

Some of Shaoyi Li's notable coworkers include Ellen Filvaroff and Kristen Mae Hege. Their collaborative efforts have played a crucial role in the development of new therapeutic strategies and enhancing the understanding of hepatocellular carcinoma.

Conclusion

Shaoyi Li's contributions to the treatment of hepatocellular carcinoma represent a significant advancement in medical innovation. His patent and ongoing work at Celgene Corporation highlight the importance of research and collaboration in the fight against cancer.